Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$1.58 +0.6%	$1.42	$1.05 ▼ $5.17	$171.08M	0.38	1.20 million shs	902,887 shs
CGEN Compugen	$1.59	$1.57	$1.13 ▼ $2.66	$141.89M	2.57	365,263 shs	218,945 shs
NVCT Nuvectis Pharma	$8.22 +4.3%	$8.71	$4.44 ▼ $11.80	$171.75M	-0.25	134,066 shs	201,162 shs
STTK Shattuck Labs	$0.82 +0.6%	$0.98	$0.69 ▼ $4.99	$39.28M	1.63	333,453 shs	67,248 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	+0.64%	+8.22%	+7.48%	+41.07%	+19.70%
CGEN Compugen	0.00%	-7.56%	-3.05%	+15.22%	-9.66%
NVCT Nuvectis Pharma	+4.31%	+4.71%	-2.26%	-13.75%	+24.92%
STTK Shattuck Labs	+0.55%	+6.22%	-18.81%	+0.05%	-80.43%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACRS Aclaris Therapeutics	2.2202 of 5 stars	3.6	1.0	2.7	1.7	0.6
CGEN Compugen	1.6203 of 5 stars	3.5	2.0	2.7	0.0	0.0
NVCT Nuvectis Pharma	3.3494 of 5 stars	3.5	0.0	4.4	5.0	0.6
STTK Shattuck Labs	3.6971 of 5 stars	3.4	5.0	3.3	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRS Aclaris Therapeutics	3.11	Buy	$8.71	451.54% Upside
CGEN Compugen	3.00	Buy	$4.00	151.57% Upside
NVCT Nuvectis Pharma	3.00	Buy	$17.00	106.81% Upside
STTK Shattuck Labs	2.83	Moderate Buy	$7.50	814.63% Upside

Current Analyst Ratings Breakdown

Latest STTK, NVCT, CGEN, and ACRS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	ACRS Aclaris Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$6.00
6/25/2025	ACRS Aclaris Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/23/2025	ACRS Aclaris Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$8.00
5/28/2025	ACRS Aclaris Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$8.00
5/14/2025	ACRS Aclaris Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $16.00
5/9/2025	ACRS Aclaris Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$15.00 ➝ $9.00
4/30/2025	NVCT Nuvectis Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $15.00

(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRS Aclaris Therapeutics	$18.72M	9.14	N/A	N/A	$1.44 per share	1.10
CGEN Compugen	$27.86M	5.09	N/A	N/A	$0.62 per share	2.56
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	$0.50 per share	N/A
STTK Shattuck Labs	$5.72M	6.87	N/A	N/A	$1.67 per share	0.49

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRS Aclaris Therapeutics	-$132.07M	-$1.39	N/A	N/A	N/A	-732.42%	-30.73%	-22.74%	8/6/2025 (Estimated)
CGEN Compugen	-$14.23M	-$0.16	N/A	N/A	N/A	-51.27%	-24.51%	-12.19%	8/5/2025 (Estimated)
NVCT Nuvectis Pharma	-$19M	-$1.13	N/A	N/A	N/A	N/A	-148.83%	-95.60%	8/5/2025 (Estimated)
STTK Shattuck Labs	-$75.41M	-$1.39	N/A	N/A	N/A	N/A	-79.69%	-69.13%	7/30/2025 (Estimated)

Latest STTK, NVCT, CGEN, and ACRS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	STTK Shattuck Labs	-$0.25	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	ACRS Aclaris Therapeutics	-$0.14	N/A	N/A	N/A	$1.34 million	N/A
8/5/2025	Q2 2025	CGEN Compugen	-$0.07	N/A	N/A	N/A	$3.95 million	N/A
8/5/2025	Q2 2025	NVCT Nuvectis Pharma	-$0.25	N/A	N/A	N/A	N/A	N/A
5/19/2025	Q1 2025	CGEN Compugen	-$0.06	-$0.08	-$0.02	-$0.08	$3.70 million	$2.28 million
5/6/2025	Q1 2025	ACRS Aclaris Therapeutics	-$0.19	-$0.12	+$0.07	-$0.12	$3.55 million	N/A
5/6/2025	Q1 2025	NVCT Nuvectis Pharma	-$0.30	-$0.27	+$0.03	-$0.27	N/A	N/A
5/1/2025	Q1 2025	STTK Shattuck Labs	-$0.29	-$0.27	+$0.02	-$0.27	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRS Aclaris Therapeutics	N/A	N/A	N/A	N/A	N/A
CGEN Compugen	N/A	N/A	N/A	N/A	N/A
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	N/A
STTK Shattuck Labs	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRS Aclaris Therapeutics	N/A	5.06	5.06
CGEN Compugen	N/A	5.09	5.09
NVCT Nuvectis Pharma	N/A	3.28	3.28
STTK Shattuck Labs	N/A	9.08	9.08

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRS Aclaris Therapeutics	98.34%
CGEN Compugen	12.22%
NVCT Nuvectis Pharma	96.77%
STTK Shattuck Labs	58.74%

Insider Ownership

Company	Insider Ownership
ACRS Aclaris Therapeutics	6.40%
CGEN Compugen	9.50%
NVCT Nuvectis Pharma	30.52%
STTK Shattuck Labs	12.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRS Aclaris Therapeutics	100	108.28 million	101.35 million	Optionable
CGEN Compugen	70	89.24 million	80.76 million	Optionable
NVCT Nuvectis Pharma	8	20.89 million	14.52 million	Not Optionable
STTK Shattuck Labs	100	47.90 million	42.15 million	Optionable

STTK, NVCT, CGEN, and ACRS Headlines

Recent News About These Companies

Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism

July 2, 2025 | globenewswire.com

Shattuck Labs, Inc. (STTK) - Yahoo Finance

June 28, 2025 | finance.yahoo.com

Here's Why We're Watching Shattuck Labs' (NASDAQ:STTK) Cash Burn Situation

June 13, 2025 | finance.yahoo.com

Shattuck Labs Advances SL-325 Program Amid Financial Progress

May 5, 2025 | tipranks.com

Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 1, 2025 | globenewswire.com

Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference

April 2, 2025 | globenewswire.com

Shattuck Labs Full Year 2024 Earnings: Misses Expectations

March 29, 2025 | uk.finance.yahoo.com

Shattuck Labs reports Q4 EPS (37c), consensus (32c)

March 28, 2025 | markets.businessinsider.com

H.C. Wainwright Reaffirms Their Hold Rating on Shattuck Labs (STTK)

March 28, 2025 | markets.businessinsider.com

Shattuck Labs, Inc.: Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

March 27, 2025 | finanznachrichten.de

Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

March 27, 2025 | globenewswire.com

Leerink Partners Initiates Coverage of Shattuck Labs (STTK) with Outperform Recommendation

March 18, 2025 | msn.com

Shattuck Labs initiated with an Outperform at Leerink

March 17, 2025 | markets.businessinsider.com

Favourable Signals For Shattuck Labs: Numerous Insiders Acquired Stock

March 11, 2025 | finance.yahoo.com

H.C. Wainwright Keeps Their Hold Rating on Shattuck Labs (STTK)

February 21, 2025 | markets.businessinsider.com

Shattuck Labs’ SL-325 shows positive results in inflammatory bowel disease

February 20, 2025 | markets.businessinsider.com

Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

February 20, 2025 | globenewswire.com

Shattuck Labs to Present Pre-Clinical Data on SL-325 at ECCO 2025 Conference in Berlin

February 13, 2025 | quiverquant.comQ

Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

February 13, 2025 | globenewswire.com

Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn’s and Colitis Congress

February 4, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

STTK, NVCT, CGEN, and ACRS Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

$1.58 +0.01 (+0.64%)

Closing price 07/14/2025 04:00 PM Eastern

Extended Trading

$1.59 +0.01 (+0.63%)

As of 07/14/2025 06:25 PM Eastern

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Compugen NASDAQ:CGEN

$1.59 0.00 (0.00%)

Closing price 07/14/2025 04:00 PM Eastern

Extended Trading

$1.60 +0.01 (+0.63%)

As of 07/14/2025 06:48 PM Eastern

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Nuvectis Pharma NASDAQ:NVCT

$8.22 +0.34 (+4.31%)

Closing price 07/14/2025 04:00 PM Eastern

Extended Trading

$8.23 +0.01 (+0.12%)

As of 07/14/2025 04:05 PM Eastern

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Shattuck Labs NASDAQ:STTK

$0.82 +0.00 (+0.55%)

Closing price 07/14/2025 04:00 PM Eastern

Extended Trading

$0.81 -0.01 (-0.73%)

As of 07/14/2025 05:42 PM Eastern

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time